ORSERDU

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug ORSERDU contains one active pharmaceutical ingredient (API):

1	Elacestrant UNII FM6A2627A8 - ELACESTRANT
	Elacestrant, a tetrahydronaphthalene compound, is a potent, selective and orally active estrogen receptor-α (ERα) antagonist and degrader. Elacestrant inhibits the estradiol-dependent and independent growth of ERα-positive breast cancer cells, including models harbouring estrogen receptor 1 (ESR1) gene mutations.
	Read more about Elacestrant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ORSERDU Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ORSERDU Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BA	Anti-estrogens	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents
Discover more medicines within L02BA

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3044708, 3044719
FR	Base de données publique des médicaments	67179699, 69242739
IT	Agenzia del Farmaco	050896012, 050896024
LT	Valstybinė vaistų kontrolės tarnyba	1097798, 1097799
US	FDA, National Drug Code	72187-0101, 72187-0102